Aktiesnakken — Marts 2010
-
Finanshuset Alpha Value har opjusteret anbefalingen af aktien i
biotekselskabet Genmab fra "reducer" til "køb". -
Samtidig reducerer
finanshuset dog kursmålet på aktien fra 94,50 kr. til 93,6 kr -
hahhahaha alpha value to the rescue. har vi nogen sinde fundet ud af hvem der står bag
-
hahahaha endnu bedre de har været igang med brøkregningen !!!
-
jobono godmorgen -
Genmab A/S (OMX: GEN) offentliggjorde i
dag, at selskabets President, R&D & Chief Scientific Officer, Prof. Jan van de
Winkel, ph.d., deltager på Kempen & Co. Life Sciences Konferencen den 23. marts
i Bruxelles, Belgien -
stinker? vi kan handle vores Tower idag...
-
med hele 4% fortjeneste nu

-
eller også har de bare haft en beholdning at lege med....
-
for de købte fint ind af t-retterne
-
3,4 mio t-retter mener jeg
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind